Premium
Sequence variants in the human 25‐hydroxyvitamin D 3 1‐α‐hydroxylase (CYP27B1) gene are not associated with prostate cancer risk
Author(s) -
Hawkins Gregory A.,
Cramer Scott D.,
Zheng Siqun L.,
Isaacs Sarah D.,
Wiley Kathy E.,
Chang BaoLi,
Bleecker Eugene R.,
Walsh Patrick C.,
Meyers Deborah A.,
Isaacs William B.,
Xu Jianfeng
Publication year - 2002
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10144
Subject(s) - prostate cancer , single nucleotide polymorphism , genotype , prostate , biology , allele , calcitriol receptor , vitamin d and neurology , endocrinology , medicine , cancer , gene , genetics
BACKGROUND 1,25‐dihydroxyvitamin D 3 has been shown to have antiproliferative properties on normal and neoplastic prostatic cells. 25‐hydroxyvitamin D 3 1‐α‐hydroxylase, the enzyme that catalyzes the final step of vitamin D synthesis, converting 25‐hydroxyvitamin D 3 to 1,25‐dihydroxyvitamin D 3 , is expressed in the prostate. METHODS The human 25‐hydroxyvitamin D 3 1‐α‐hydroxylase gene (CYP27B1) was resequenced in a case/control panel consisting of 64 individuals (48 Caucasians and 16 African Americans), with equal numbers of hereditary prostate cancer cases, sporadic cases, and unaffected controls. Three frequent single nucleotide polymorphisms (SNPs) were genotyped in 245 prostate cancer cases and 222 controls. RESULTS Six noncoding SNPs were identified in the CYP27B1 gene. No significant difference was found in allele and genotype frequencies between sporadic cases and unaffected controls for the three genotyped SNPs. CONCLUSION This study suggests that the CYP27B1 gene does not play a major role as a prostate cancer susceptibility gene. Prostate 53: 175–178, 2002. © 2002 Wiley‐Liss, Inc.